tbuckley/cabot-search huggingface dataset:
In acute stroke or TIA, ticagrelor did not differ from aspirin for a composite of stroke, MI, or death at 90 days
Authors: Miriam L. Priglinger
Journal: Annals of Internal Medicine (2016)

Source Citation Johnston SC, Amarenco P, Albers GW, et al; SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016 May 10. [Epub ahead of print] 27160892
Synthetic virus-like particles prepared via protein corona formation enable effective vaccination in an avian model of coronavirus infection
Authors: Hui-Wen Chen, Chen-Yu Huang, Shu-Yi Lin, Zih-Syun Fang, Chen-Hsuan Hsu, Jung-Chen Lin, Yuan-I Chen, Bing-Yu Yao, Che-Ming J. Hu
Journal: Biomaterials (2016)
Unicar: A Novel Modular Retargeting Platform Technology for CAR T Cells
Authors: Marc Cartellieri, Simon Loff, Malte von Bonin, Elham P. Bejestani, Armin Ehninger, Anja Feldmann, Stefanie Koristka, Claudia Arndt, Gerhard Ehninger, Michael P Bachmann
Journal: Blood (2015)
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary
Authors: Valentin Fuster, Lars E. Rydén, David S. Cannom, Harry J. Crijns, Anne B. Curtis, Kenneth A. Ellenbogen, Jonathan L. Halperin, Jean-Yves Le Heuzey, G. Neal Kay, James E. Lowe, S. Bertil Olsson, Eric N. Prystowsky, Juan Luis Tamargo, Samuel Wann, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffery L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon Ann Hunt, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel, Silvia G. Priori, Jean-Jacques Blanc, Andrzej Budaj, A. John Camm, Veronica Dean, Jaap W. Deckers, Catherine Despres, Kenneth Dickstein, John Lekakis, Keith McGregor, Marco Metra, Joao Morais, Ady Osterspey, Juan Luis Tamargo, José Luis Zamorano
Journal: Circulation (2006)
Risk of cancer in patients with polycystic kidney disease: a propensity-score matched analysis of a nationwide, population-based cohort study
Authors: Tung-Min Yu, Ya-Wen Chuang, Mei-Ching Yu, Cheng-Hsu Chen, Cheng-Kuang Yang, Shih-Ting Huang, Cheng-Li Lin, Kuo-Hsiung Shu, Chia-Hung Kao
Journal: The Lancet Oncology (2016)
Haploidentical Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acquired Severe Aplastic Anemia: Collaborative Study of Three Eastern Asian Countries
Authors: Ho Joon Im, Kyung Nam Koh, Yoshiyuki Takahashi, Chengjuan Luo, Seiji Kojima, Jing Chen, Jong Jin Seo
Journal: Blood (2014)
Postpartum Psychosis: Madness, Mania, and Melancholia in Motherhood
Authors: Veerle Bergink, Natalie Rasgon, Katherine L. Wisner
Journal: American Journal of Psychiatry (2016)

Psychosis or mania after childbirth is a psychiatric emergency with risk for suicide and infanticide.The authors reviewed the epidemiologic and genetic research and physiological postpartum triggers (endocrine, immunological, circadian) of psychosis. They also summarized all systematic reviews and synthesized the sparse clinical studies to provide diagnostic recommendations, treatment options, and strategies for prevention.The incidence of first-lifetime onset postpartum psychosis/mania from population-based register studies of psychiatric admissions varies from 0.25 to 0.6 per 1,000 births. After an incipient episode, 20%-50% of women have isolated postpartum psychosis. The remaining women have episodes outside the perinatal period, usually within the bipolar spectrum. Presumably, the mechanism of onset is related to physiological changes after birth (e.g., hormonal, immunological, circadian), which precipitate disease in genetically vulnerable women. Some women have treatable causes and comorbidities, such as autoimmune thyroiditis or infections. N-methyl-d-aspartate-encephalitis or inborn errors of metabolism may present after birth with psychosis. Fewer than 30 publications have focused on the treatment of postpartum psychosis. The largest study (N=64) provided evidence that lithium is highly efficacious for both acute and maintenance treatment. Another report (N=34) described successful ECT treatment. Inpatient care is usually required to ensure safety, complete the diagnostic evaluation, and initiate treatment. The relapse risk after a subsequent pregnancy for women with isolated postpartum psychoses is 31% (95% CI=22-42). Strategies for prevention of postpartum psychosis include lithium prophylaxis immediately postpartum and proactive safety monitoring.Postpartum psychosis offers an intriguing model to explore etiologic contributions to the neurobiology of affective psychosis.
Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.
Authors: Anas Younes, Luis Y. Fayad, Andre Goy, Peter McLaughlin, Barbara Pro, Jorge Romaguera, Fredrick Hagemeister, Maria A. Rodriguez, Felipe Samaniego, Larry Kwak, Sattva Neelapu, L. Jeffrey Medeiros, Amanda Wedgwood, Michelle Fanale
Journal: Blood (2006)
Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE).
Authors: M. N. Saleh, J. C. Bendell, A. Rose, P. Siegel, L. L. Hart, S. Sirpal, S. F. Jones, E. Crowley, R. Simantov, L. T. Vahdat
Journal: Journal of Clinical Oncology (2010)

1095
Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea
Authors: Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Haifeng Zhang, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi
Journal: Blood (2014)
The Endothelial Antigen ESAM Monitors Reversible Conversion of Hematopoietic Stem Cells Between Dormancy and Self-Renewal
Authors: Takao Sudo, Takafumi Yokota, Tatsuki Sugiyama, Tatsuro Ishida, Yusuke Satoh, Kenji Oritani, Takashi Nagasawa, Yuzuru Kanakura
Journal: Blood (2011)
Facial Erythematous Papules in a Young Woman
Authors: Jihane Abou Rahal, Olivier Cogrel, Bernard Cribier
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
The Predictive Capabilities of Clinical Tests: The 6-Minute Walk-Reply
Authors: Vera Bittner
Journal: JAMA (1994)

<h3>In Reply.</h3> —Dr Mark suggests three criteria by which clinicians should judge a new clinical maneuver. The first is the amount of prediction: We agree that both absolute risks and RRs should be considered and have provided information on both in our article. Relative risks are most useful when comparing one predictive variable with another in the same patient population. In our study, for example, the point estimates of the two statistically significant odds ratios (ORs) for death were 1.74 for a 15% decrement in ejection fraction and 1.5 for a 120-m decrement in walking distance. These results indicate to the clinician that walking distance was the second-best predictor of prognosis among the variables evaluated in our model and was nearly as good a predictor as ejection fraction. Absolute risk is more relevant when the test is applied to a single patient. In our population, the risk of dying increased
Thinking Outside the (Lunch) Box
Authors: Sean C. Lucan
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increased Clearance Explains the Ultra-Large Multimers in Von Willebrand Disease Type 2M Vicenza; Lessons from Recombinant VWF Vicenza and Modeling of Multimer Catabolism.
Authors: András Gézsi, Gábor Balázsi, Krisztina Sallai, Adrienn Mohl, Eszter Nagy, Teréz Szabó, J. Evan Sadler, Imre Bodó
Journal: Blood (2004)
Implants for the aged patient: biological, clinical and sociological considerations
Authors: P. Mark Bartold, Saso Ivanovski, Ivan Darby
Journal: Periodontology 2000 (2016)

Abstract Until recently, age, particularly old age, was considered a contraindication to the placement of dental implants. However, this was based largely on anecdotal dogma rather than on empirical information. This review considers the biological, clinical and socio‐economic implications of implants placed in the aged population. Aging has been shown to have an influence on the biological aspects of soft‐ and hard‐tissue wound healing and tissue remodeling, which may influence the establishment and maintenance of implant integration. However, information to date indicates that age should not be an a priori contraindication for implant placement and there is good evidence to indicate that dental implants can be placed successfully in the elderly with good clinical and socio‐economic outcomes.
A young man with recurrent limb shaking
Authors: Ke-Hua Pan, Ming-Hua Zheng
Journal: BMJ (2016)

A 24 year old man underwent a clinical examination because of recurrent limb shaking. Physical and mental examination revealed no abnormalities. Magnetic resonance imaging (MRI) was performed and a sagittal T1 weighted image obtained (fig 1⇓). What is the diagnosis? …
Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients
Authors: Massimo Gentile, Tait D. Shanafelt, Davide Rossi, Luca Laurenti, Francesca R. Mauro, Stefano Molica, Giovanna Cutrona, Giuseppina Uccello, Melissa Campanelli, Ernesto Vigna, Giovanni Tripepi, Kari G. Chaffee, Sameer A. Parikh, Sabrina Bossio, Anna Grazia Recchia, Idanna Innocenti, Raffaella Pasquale, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Robin Foà, Fortunato Morabito
Journal: Blood (2016)
Mortality Among Hispanics
Authors: Richard Scribner
Journal: JAMA (1994)

<h3>To the Editor.</h3> —There is a bias among US institutional researchers against a behavioral explanation of the "paradox" of Hispanic health. In 1991 the Centers for Disease Control speculated that the low rate of infant mortality among Mexican Hispanics was because of unrecorded out-of-hospital births.<sup>1</sup>Now the National Heart, Lung, and Blood Institute attributes the low mortality among Mexican Hispanics compared with non-Hispanics to a "healthy migrant effect."<sup>1</sup>These institutional researches are misleading both the research community and the public with regard to an important epidemiologic discovery. The bias appears to stem from the incapability of institutional researchers to acknowledge that the actual causes of death in the United States are no longer biological but behavioral. Sorlie et al present data demonstrating that overall mortality in Hispanics is lower than in non-Hispanics despite their unfavorable socioeconomic circumstances.<sup>2</sup>However, the authors never acknowledge that in terms of actual
Targeting eIF5A Hypusination Prevents Anoxic Cell Death through Mitochondrial Silencing and Improves Kidney Transplant Outcome
Authors: Nicolas Melis, Isabelle Rubera, Marc Cougnon, Sébastien Giraud, Baharia Mograbi, Amine Belaid, Didier F. Pisani, Stephan M. Huber, Sandra Lacas-Gervais, Konstantina Fragaki, Nicolas Blondeau, Paul Vigne, Christian Frelin, Thierry Hauet, Christophe Duranton, Michel Tauc
Journal: Journal of the American Society of Nephrology (2016)

The eukaryotic initiation factor 5A (eIF5A), which is highly conserved throughout evolution, has the unique characteristic of post-translational activation through hypusination. This modification is catalyzed by two enzymatic steps involving deoxyhypusine synthase (DHPS) and deoxyhypusine hydroxylase (DOHH). Notably, eIF5A may be involved in regulating the lifespan of Drosophila during long-term hypoxia. Therefore, we investigated the possibility of a link between eIF5A hypusination and cellular resistance to hypoxia/anoxia. Pharmacologic targeting of DHPS by N 1-guanyl-1,7-diaminoheptane (GC7) or RNA interference–mediated inhibition of DHPS or DOHH induced tolerance to anoxia in immortalized mouse renal proximal cells. Furthermore, GC7 treatment of cells reversibly induced a metabolic shift toward glycolysis as well as mitochondrial remodeling and led to downregulated expression and activity of respiratory chain complexes, features characteristic of mitochondrial silencing. GC7 treatment also attenuated anoxia-induced generation of reactive oxygen species in these cells and in normoxic conditions, decreased the mitochondrial oxygen consumption rate of cultured cells and mice. In rats, intraperitoneal injection of GC7 substantially reduced renal levels of hypusinated eIF5A and protected against ischemia-reperfusion–induced renal injury. Finally, in the preclinical pig kidney transplant model, intravenous injection of GC7 before kidney removal significantly improved graft function recovery and late graft function and reduced interstitial fibrosis after transplant. This unconventional signaling pathway offers an innovative therapeutic target for treating hypoxic-ischemic human diseases and organ transplantation.
Phase II trial of temozolomide for leptomeningeal metastases: Safety and activity analysis.
Authors: P. Pérez Segura, M. Gil, C. Balañá, I. Chacón, J. Muñoz Langa, M. Martin
Journal: Journal of Clinical Oncology (2010)

e12528 Background: Leptomeningeal carcinomatosis represents a fatal complication of solid tumors. Unfortunately, therapeutic options remain limited, particularly for patients with chemoresistant tumors. Optimized treatment remains controversial and may rely upon a combination of chemotherapy (intrathecal and/or intravenous) and concurrent focal radiotherapy. We evaluated the response rate, survival, quality of life (QoL) and safety when temozolomide (TMZ) was used as first-line treatment in patients (pts) with solid tumors known to metastasize to the brain: leptomeningeal metastases (LM) of breast cancer (BC), non small cell lung cancer (NSCLC) and melanoma (MEL). Methods: Eligible pts had LM from BC, NSCLC and MEL documented by positive CSF cytology or compatible clinical syndrome with diagnostic MRI, with adequate hematologic and renal function. Prior therapy for LM was not permitted. Pts received oral TMZ (100 mg/m2 daily) week-on, week-off. CSF sampling was repeated every 4 weeks. MRI scans were repeated every 8 weeks. The SF-36 questionnaire was used to collect QoL data. A two-stage study design was used: 21 pts initially; if at least 3 responses were seen, 29 more pts were to be enrolled, giving statistical power of 0.90 to detect a response rate (RR) of 16%. Results: 19 pts have been enrolled (the trial was stopped early due to lack of pt accrual): BC (10 pts), NSCLC (7), MEL (1) and BC+NSCLC (1). 19 pts previously received various chemotherapy regimens (median 3) and 14 pts previously received radiotherapy. Median PFS was 80%. Therapy was well tolerated. Maximum treatment-related toxicity: grade 3/4 lymphopenia in 1 pt; grade 3 emesis 1 pt. Only 1 pt required dose modifications (hematologic adverse event). 16 pts progressed. 2 pts had a partial response (PR), 1 pt stable disease (SD) (15.79% clinical benefit). Median survival has not been reached, with a median time to progression (mTTP) of 28 days; treatment did not adversely affect QOL scores. Conclusions: TMZ was well tolerated at this schedule in pts with LM. This schedule may be active in these patients (RR 15.79%). QoL was not affected by treatment. No significant financial relationships to disclose.
Immune responses and association with clinical outcome of advanced colorectal cancer patients treated with the multi-peptide vaccine IMA910.
Authors: Sabrina Kuttruff, Toni Weinschenk, Oliver Schoor, Juha Lindner, Sarah Kutscher, Dominik Maurer, Andrea Mayer-Mokler, Joerg Ludwig, Elzbieta Nowara, Laszlo Torday, Jozsef Cseh, Thomas Hoehler, Erika Hitre, Tim Maughan, Richard A. Adams, Frank Mayer, Carsten Reinhardt, Harpreet Singh, Steffen Walter
Journal: Journal of Clinical Oncology (2012)

2522 Background: IMA910 is a novel multi-peptide cancer vaccine consisting of 10 HLA class I and 3class II tumor-associated peptides (TUMAPs), which were selected based on natural presentation on colorectal tumors by the XPRESIDENT antigen discovery platform. Methods: 92 HLA-A*02+ advanced colorectal cancer (aCRC) patients (pts) with stable or responding disease after 12 weeks of first-line oxaliplatin-based therapy were enrolled in this phase I/II trial. After pre-treatment with cyclophosphamide (300 mg/m 2 ), patients were immunized intradermally with IMA910 plus the immune modulator GM-CSF without (cohort 1; n=66) or with (cohort 2; n=26) topically applied imiquimod, another immune modulator acting via toll-like receptor 7 on antigen presenting cells. T-cell responses to individual IMA910 peptides were analyzed by HLA multimer and intracellular cytokine staining (ICS) assays. Results: IMA910 elicited immune responses towards multiple class I (43%) and class II TUMAPs (65%). 34% of pts responded to multiple class I and class II TUMAPs. Pts that received imiquimod were more often multi-peptide class I responders in the ICS assay (p=0.016) and showed an approx. 2x higher frequency of T-cell response (p=0.12). Responses to multiple class I and class II TUMAPs were associated with higher disease control rate at all time points (all p&lt;0.02), increased time to progression (p=0.006), progression-free survival (p=0.009) and OS (p=0.088, HR=0.53). Baseline characteristics of multi vs. non-multi responders were overall well comparable. In a prospectively defined, blinded matched-pair analysis with patients in arm C of the COIN trial, multi-peptide responder patients showed a prolonged survival vs. corresponding COIN patients (p=0.04), while the non-multi responder patients had comparable survival. Conclusions: IMA910 is immunogenic. Imiquimod increases the quality of immune responses. Responses to multiple TUMAPs are associated with better clinical outcome. Several observations indicate that this association is not a reflection of better prognosis of the immunologically responding subset of patients. These results suggest further development of IMA910.
Harrison C Spencer
Authors: Martin McKee
Journal: BMJ (2016)

Global leader in public health training and research



The challenges facing public health today are incredibly complex. Climate change; a seemingly never ending succession of newly emerging or re-emerging diseases, including antimicrobial resistance; conflict; mass migration; and political, economic, and social change all require innovative thinking by public health workers, researchers, policy makers, and practitioners. If they are to make a difference they must deploy a wide range of skills, both technical and political. Harrison Spencer, who has died in Washington aged 71, made an enormous contribution over almost 50 years to preparing the public health workforce for these challenges.

In 1996 he became the first person from outside the UK to be appointed dean of the London School of Hygiene and Tropical Medicine (LSHTM). In his four years there he led a substantial expansion of the school’s activities in both research and teaching. 

Recognising the ways in which the changing global landscape was impacting on funding for health research, he worked assiduously to strengthen the school’s presence in North America. This paved the way for a $40 million award in 2000—the first of its kind from the Bill and Melinda Gates Foundation—for …
Cisplatin plus gemcitabine (GC) as induction chemotherapy in locally advanced head and neck cancer (HANC)
Authors: A. Jamshed, R. Hussain, S. Ahmed, K. Rehman, K. Shehzad, B. Muhammad, S. Hameed, M. A. Shah, R. Azhar, Z. Faruqui
Journal: Journal of Clinical Oncology (2007)

6073 Background: Cisplatin/infusional 5-fluorouracil chemotherapy is routinely administered as standard induction chemotherapy in advanced HANC. However, the optimum treatment remains to be defined. Gemcitabine is an active agent in HANC and few studies have evaluated induction GC in HANC. We have explored the activity and toxicity of GC as induction treatment in HANC and report the results. Methods: From August 2005 to September 2006, 55 patients with locally advanced HANC had induction chemotherapy with GC at Shaukat Khanum Memorial Cancer Hospital and Research Centre. We reviewed the medical records and prospectively collected data to determine activity and toxicity of induction GC. M:F ratio was 64%:36% with a median age of 50 years (range 19–80). All patients had histologically confirmed squamous cell carcinoma. The site of disease was nasopharynx, paranasal sinuses, oral cavity, oropharynx, larynx and hyopharynx in 4% (2), 11% (6), 51% (21), 2% (1), 11% (6) and 22% (11) respectively. According to AJCC staging 7% (4) had stage III and 93% (51) had stage IVa/IVb disease (T3N0 7%, T3N+ 2%, T4N0 38% and T4N+ 53%). Induction chemotherapy consisted of 2 cycles of cisplatin 75 mg/m 2 day 1 and gemcitabine 1000 mg/m 2 day 1 and 8 with treatment repeated three weekly. Fifty-three (94%) patients received 2 cycles as planned. Toxicity was scored after each cycle according to the NCI.CTC criteria. Response was assessed following completion of induction chemotherapy by clinical examination/MRI scan. Results: All patients were available for assessment of toxicity and response. A total of 111 cycles were delivered. The response rates are: complete 24% (13), partial 62% (34), no response 7% (4) and progression 7% (4). The overall response rate was 86% (complete 24%, partial 62%). No treatment related deaths occurred. Haematological G3/G4 toxicity included neutropenia (13%/7%) and thrombocytopenia (5%/0%). The non-haematological toxicity observed (nausea, vomiting and diarrhoea) was only G1/G2. Conclusions: GC is well tolerated with low toxicity and high anti tumour activity as neoadjuvant chemotherapy treatment in squamous cell head and neck cancer. Combination GC arm should be included in future trials. No significant financial relationships to disclose.